Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria
- PMID: 11120995
- PMCID: PMC90290
- DOI: 10.1128/AAC.45.1.345-348.2001
Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria
Abstract
The activity of ABT-773, a novel ketolide antibiotic, against clinical isolates of anaerobic bacteria was determined and compared to the activities of other antimicrobial agents. MICs at which 90% of isolates were inhibited (MIC(90)s) were </=0.06 microg/ml for Actinomyces spp., Clostridium perfringens, Peptostreptococcus spp., Propionibacterium spp., and Porphyromonas spp. The MIC(50)s and MIC(90)s were </=0.06 and >32 microg/ml, respectively, for Eubacterium spp., Lactobacillus spp., Clostridium difficile, and Clostridium ramosum. The MIC(90) for Bilophila wadsworthia, Bacteroides ureolyticus, and Campylobacter gracilis was 1 microg/ml, and that for Prevotella bivia and other Prevotella spp. was 0.5 microg/ml. The MIC(90) for Fusobacterium nucleatum was 8 microg/ml, and that for Fusobacterium mortiferum and Fusobacterium varium was >32 microg/ml. The MIC(90)s for the Bacteroides fragilis group were as follows: for B. fragilis, 8 microg/ml; for Bacteroides thetaiotaomicron, Bacteroides ovatus, Bacteroides distasonis, and Bacteroides uniformis, >32 microg/ml; and for Bacteroides vulgatus, 4 microg/ml. Telithromycin MICs for the B. fragilis group were usually 1 to 2 dilutions higher than ABT-773 MICs. For all strains, ABT-773 was more active than erythromycin by 4 or more dilutions, and for some strains this drug was more active than clindamycin.
Similar articles
-
In vitro activity of telithromycin (HMR 3647) against 502 strains of anaerobic bacteria.J Antimicrob Chemother. 2001 Apr;47(4):467-9. doi: 10.1093/jac/47.4.467. J Antimicrob Chemother. 2001. PMID: 11266423
-
Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003.J Antimicrob Chemother. 2006 May;57(5):992-8. doi: 10.1093/jac/dkl052. Epub 2006 Feb 28. J Antimicrob Chemother. 2006. PMID: 16507560
-
Comparative in vitro activities of ABT-773 against aerobic and anaerobic pathogens isolated from skin and soft-tissue animal and human bite wound infections.Antimicrob Agents Chemother. 2000 Sep;44(9):2525-9. doi: 10.1128/AAC.44.9.2525-2529.2000. Antimicrob Agents Chemother. 2000. PMID: 10952607 Free PMC article.
-
In vitro activity of ertapenem: review of recent studies.J Antimicrob Chemother. 2004 Jun;53 Suppl 2:ii11-21. doi: 10.1093/jac/dkh204. J Antimicrob Chemother. 2004. PMID: 15150179 Review.
-
Activity of a novel carbapenem, doripenem, against anaerobic pathogens.Diagn Microbiol Infect Dis. 2009 Apr;63(4):447-54. doi: 10.1016/j.diagmicrobio.2009.01.022. Epub 2009 Feb 26. Diagn Microbiol Infect Dis. 2009. PMID: 19249176 Review.
Cited by
-
The ketolides: a critical review.Drugs. 2002;62(12):1771-804. doi: 10.2165/00003495-200262120-00006. Drugs. 2002. PMID: 12149046 Review.
-
In vitro activities of ABT-773, a new ketolide, against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.Antimicrob Agents Chemother. 2001 Aug;45(8):2363-7. doi: 10.1128/AAC.45.8.2363-2367.2001. Antimicrob Agents Chemother. 2001. PMID: 11451698 Free PMC article.
-
Activities of ABT-773 against microaerophilic and fastidious organisms.Antimicrob Agents Chemother. 2002 Aug;46(8):2716-9. doi: 10.1128/AAC.46.8.2716-2719.2002. Antimicrob Agents Chemother. 2002. PMID: 12121965 Free PMC article.
-
Concentrations of amoxicillin and clindamycin in teeth following a single dose of oral medication.Clin Oral Investig. 2014 Jan;18(1):35-40. doi: 10.1007/s00784-013-0958-7. Epub 2013 Mar 13. Clin Oral Investig. 2014. PMID: 23508627 Clinical Trial.
References
-
- Canigia L F, Martino A D, Litterio M, Castello L, Fernandez M I, Rollett R, Greco G, Predari S, Bianchini H. Comparative in vitro activities of four macrolides at two pH values against Gram-negative anaerobic rods other than the Bacteroides fragilis group. Anaerobe. 1999;5:451–454.
-
- Edlund C, Sillerstrom E, Wahlund E, Nord C E. In vitro activity of HMR 3647 against anaerobic bacteria. J Chemother. 1998;10:280–284. - PubMed
-
- Goldstein E J C, Citron D M, Gerardo S H, Hudspeth M, Merriam C V. Activities of HMR 3004 and HMR 3647 compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans. Antimicrob Agents Chemother. 1998;42:1127–1132. - PMC - PubMed
-
- National Committee for Clinical Laboratory Standards. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 4th ed. Approved standard, NCCLS document M11–A4. Wayne, Pa: National Committee for Clinical Laboratory Standards; 1997.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous